Oct. 23 at 7:58 PM
$THAR TH104 as a prophylactic countermeasure for first responders exposed to high-potency opioids has a potential domestic TAM of around
$100M if you factor in approximately 2 million US first responders/military personnel x 40/50 a pill, that doesn’t factor in government stock piling.
Also Factor in 5 million EU/UK military/first responders, and we have 7 million potential patients and around 300-350m global TAM which excludes Asia. Company only has a 20m market cap and a tiny float of 2m+ shares.
FDA allowed company to pursue NDA without any more trials.